SubHero Banner
Text

Keytruda® (pembrolizumab) – New indication

June 29, 2020 - The FDA announced the approval of Merck’s Keytruda (pembrolizumab), for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).

Download PDF